OncoMatch/Clinical Trials/NCT06158828
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Is NCT06158828 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for aml, childhood.
Treatment: Rabbit Anti thymocyte globulin · Busulfan · Fludarabine · Thiotepa · Melphalan · TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft · memory-like natural killer cells · IL-2 · Plerixafor · Granulocyte Colony-Stimulating Factor · CliniMACS — This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: RPN1 RPN1-MECOM
RPN1-MECOM
Required: RUNX1 RUNX1-MECOM
RUNX1-MECOM
Required: NPM1 NPM1-MLF1
NPM1-MLF1
Required: DEK DEK-NUP214
DEK-NUP214
Required: KAT6A KAT6A-CREBBP
KAT6A-CREBBP (if ≥ 90 days at diagnosis)
Required: FUS FUS-ERG
FUS-ERG
Required: KMT2A (MLL) KMT2A-AFF1
KMT2A-AFF1
Required: KMT2A (MLL) KMT2A-AFDN
KMT2A-AFDN
Required: KMT2A (MLL) KMT2A-ABI1
KMT2A-ABI1
Required: KMT2A (MLL) KMT2A-MLLT1
KMT2A-MLLT1
Required: NUP98 rearrangement (any partner gene)
11p15 rearrangement (NUP98 - any partner gene)
Required: ETV6 rearrangement (any partner gene)
12p13.2 rearrangement (ETV6 - any partner gene)
Required: ETV6 deletion (loss of ETV6)
Deletion 12p to include 12p13.2 (loss of ETV6)
Required: EGR1 deletion (loss of EGR1)
Monosomy 5/Del(5q) to include 5q31 (loss of EGR1)
Required: FLT3 ITD with allelic ratio > 0.1%, without bZIP CEBPA or NPM1
FLT3/ITD with allelic ratio > 0.1%, without bZIP CEBPA or NPM1
Prior therapy
Must have received: hematopoietic cell transplant
One prior hematopoietic cell transplant is allowed, provided remission criteria as defined above are met.
Lab requirements
Kidney function
GFR ≥ 60 mL/min/1.73m2 or serum creatinine < 2 x IULN for age/gender
Liver function
Total bilirubin ≤ 3 x IULN for age; AST(SGOT)/ALT(SGPT) ≤ 5 x IULN for age
Cardiac function
LVEF at rest ≥50% or shortening fraction (SF) ≥27% (via echocardiogram or MUGA)
Adequate organ function as defined below: Total bilirubin ≤ 3 x IULN for age; AST(SGOT)/ALT(SGPT) ≤ 5 x IULN for age; GFR ≥ 60 mL/min/1.73m2...serum creatinine < 2 x IULN for age/gender. Adequate cardiac function, defined by LVEF at rest ≥50% or SF ≥27%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify